SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer-Reference-Cited by-同舟云学术

SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

Published:2024-09-05 Issue:11 Volume:73 Page:
ISSN:1432-0851
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Li Jin,Bai Yuxian,Chen Zhendong,Ying Jieer,Guo Yabing,Fang Weijia,Zhang Feng,Xiong Jianping,Zhang Tao,Meng Zhiqiang,Zhang Jingdong,Ren Zhenggang,Hao Chunyi,Chen Yajin,Lin Xiaoyan,Pan Hongming,Zhou Fuxiang,Li Xin,Yu Fan,Zhang Juan,Zhang Zhang,Qin Shukui

Funder

BeiGene, Ltd

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00262-024-03806-2.pdf

Reference40 articles.

1. Akinyemiju T, Abera S et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease study 2015. JAMA Oncol 3:1683–1691

2. Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens V, Soerjomataram I (2022) Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer 161:108–118. https://doi.org/10.1016/j.ejca.2021.11.023

3. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S (2017) Gastric adenocarcinoma. Nat Rev Dis Primers 3:17036. https://doi.org/10.1038/nrdp.2017.36

4. Casamayor M, Morlock R, Maeda H, Ajani J (2018) Targeted literature review of the global burden of gastric cancer. ecancer 12:883. https://doi.org/10.3332/ecancer.2018.883

5. Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, Zheng L, Pan CX (2023) Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol 12:10. https://doi.org/10.1186/s40164-023-00372-8